SCHEMBL3261337

SCHEMBL3261337

C=CCN(CC=C)C([NH])C=C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2578714 0.69 ALDH1A1 (0.31)
SCHEMBL526564 0.67 ALDH1A1 (0.31)
SCHEMBL3002382 0.67
SCHEMBL527637 0.67
SCHEMBL16036122 0.67
SCHEMBL476033 0.67
SCHEMBL6057564 0.67
SCHEMBL460593 0.67 ALDH1A1 (0.31)
SCHEMBL19330081 0.67
Hydrochloric Acid SCHEMBL331808 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029606-B1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2010-05-26 EP claimed
EP-2029606-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS Brystol-Myers Squibb Company (US) 2009-03-04 EP claimed
US-7456167-B2 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 US claimed
WO-2007140254-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-06 WO claimed
US-20070275947-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-11-29 US claimed
EP-1392280-A4 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF WARNER LAMBERT CO (US) 2005-11-30 EP claimed
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 US claimed
EP-1392280-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF Abbott GmbH & Co. KG (DE) 2004-03-03 EP claimed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US claimed
WO-2002089749-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF ABBOTT GMBH & CO.KG (DE) 2002-11-14 WO claimed
EP-2029606-B1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2010-05-26 EP disclosed
EP-2029606-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS Brystol-Myers Squibb Company (US) 2009-03-04 EP disclosed
US-7456167-B2 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 US disclosed
WO-2007140254-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-06 WO disclosed
US-20070275947-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-11-29 US disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US disclosed
WO-2003002202-A1 ANTITUMORAL FORMULATIONS OF THIOXANTHENONE SANOFI-SYNTHELABO (FR) 2003-01-09 WO disclosed
WO-2002089749-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF ABBOTT GMBH & CO.KG (DE) 2002-11-14 WO disclosed
EP-0929552-A1 ACRIDONE DERIVATIVES AND METHOD OF PREPARATION OF 8-HYDROXY IMIDAZOACRIDINONE DERIVATIVES BTG INTERNATIONAL LIMITED (GB) 1999-07-21 EP disclosed
WO-1998015554-A1 ACRIDONE DERIVATIVES AND METHOD OF PREPARATION OF 8-HYDROXY IMIDAZOACRIDINONE DERIVATIVES BTG INTERNATIONAL LIMITED (GB) 1998-04-16 WO disclosed